Acute chest pain (ACP) remains a diagnostic challenge in clinical practice due to its multifactorial etiology. The urgency associated with conditions like acute coronary syndrome (ACS) necessitates a comprehensive approach to ACP.
The initial evaluation of ACP should involve a detailed history, physical examination, and electrocardiogram (ECG). The clinician should consider the patient's age, gender, risk factors, and the nature of the pain. Typical ACS pain is often described as heavy or squeezing, but atypical presentations are not uncommon.
High-sensitivity cardiac troponin (hs-cTn) is the cornerstone of ACS diagnosis. If the initial hs-cTn is negative, a repeat measurement should be done in 1-2 hours. Non-cardiac causes of raised hs-cTn, such as kidney disease, should also be considered. Additional investigations may include chest X-ray, echocardiogram, or coronary angiography, depending on the clinical suspicion.
Risk stratification using validated tools like the HEART score can guide management. Low-risk patients may be managed with outpatient testing, while high-risk patients require hospitalization and invasive evaluation. The role of newer risk stratification tools, such as the PROMISE and SCOT-HEART trials, are being explored.
Management should be tailored to the underlying cause. ACS management includes antiplatelet therapy, statins, beta-blockers, and possibly revascularization. Non-cardiac causes of ACP, such as gastrointestinal or musculoskeletal conditions, require specific treatments.
ACP is a complex clinical entity requiring a comprehensive approach. Initial evaluation, diagnostic testing, risk stratification, and tailored management are crucial to improving patient outcomes. Further research is needed to refine risk stratification tools and to understand the role of novel biomarkers in ACP.
1.
Discovery reveals protein involved in Parkinson's disease also drives skin cancer
2.
The prognosis of the Slovakian PM; Kate Middleton's treatment; and drug test cheating.
3.
We Don't Always Know What's 'Best' for Our Patients
4.
New tumor therapy approach reduces costs and side effects while increasing accessibility
5.
Dual-action mRNA vaccine takes aim at aggressive skin cancer
1.
The Evolving Arsenal: A 2025 Review of Antibody-Drug Conjugates and the Future of Precision Oncology
2.
Case Study: Combining Targeted Therapy with Immunotherapy for Metastatic Melanoma
3.
Anion Gap: The Simple Calculation That Reveals Much About Your Health
4.
Contemporary Methods in Hematology Across Clinical Settings
5.
Unlocking the Potential of Cytarabine: A New Era of Cancer Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Lorlatinib in the Management of 1st line ALK+ mNSCLC (CROWN TRIAL Update)
2.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VI
3.
An Eagles View - Evidence-based discussion on Iron Deficiency Anemia- Further Talks
4.
Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option
5.
Current Scenario of Cancer- Palliative Care to Close the Care Gap
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation